Mark Whitehead
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mark Whitehead has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Mansoor Zafar
Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Gastroenterol, London, England
4 shared publications - Muhammad Toqeer
Gastroenterology, Conquest Hospital, East Sussex Healthcare NHS Trust, St. Leonards-on-Sea, GBR
2 shared publications - Tila Muhammad
Gastroenterology and Hepatology, Conquest Hospital, East Sussex Healthcare NHS Trust, St. Leonards-on-Sea, GBR
2 shared publications - Abdul Wahab Paracha
General Internal Medicine-Gastroenterology, Grange University Hospital, Cwmbran, GBR
1 shared publication - Baby Ewnetu
Acute Care Common Stem: Anaesthesia-General Internal Medicine-Emergency Medicine, Conquest Hospital, East Sussex Healthcare NHS Trust, St. Leonards-on-Sea, GBR
1 shared publication - Ian Hawley
Histopathology, Conquest Hospital, East Sussex Healthcare NHS Trust, St. Leonards-on-Sea, GBR
1 shared publication
Latest Publications
- Open Access
- 17 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21328
Vanishing Bile Duct Syndrome Associated With Non-Hodgkin’s Lymphoma and Hepatitis E Virus Infection
The vanishing bile duct syndrome (VBDS) is a condition secondary to inciting triggers resulting in destruction and eventual disappearance of intrahepatic bile ducts leading to cholestasis. The overall outcome varies and often depends on the nature of the precipitating cause. VBDS has been found to be associated with adverse drug reactions, infectious diseases, autoimmune diseases, ischemia, and humoral factors associated with malignancies and is often irreversible. The objective of this clinical case report is to highlight the need for a broad differential to include VBDS in similar scenarios to aid rapid diagnosis and management. We hope this could lead to a more favourable outcome for patients presenting with VBDS such as the one described in this case report with concurrent non-Hodgkin’s lymphoma and infection with hepatitis E virus. To the best of our knowledge, this is the first ever reported case of VBDS associated with non-Hodgkin’s lymphoma and hepatitis E virus infection.
- 17 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21328
Open AccessVanishing Bile Duct Syndrome Associated With Non-Hodgkin’s Lymphoma and Hepatitis E Virus Infection
The vanishing bile duct syndrome (VBDS) is a condition secondary to inciting triggers resulting in destruction and eventual disappearance of intrahepatic bile ducts leading to cholestasis. The overall outcome varies and often depends on the nature of the precipitating cause. VBDS has been found to be associated with adverse drug reactions, infectious diseases, autoimmune diseases, ischemia, and humoral factors associated with malignancies and is often irreversible. The objective of this clinical case report is to highlight the need for a broad differential to include VBDS in similar scenarios to aid rapid diagnosis and management. We hope this could lead to a more favourable outcome for patients presenting with VBDS such as the one described in this case report with concurrent non-Hodgkin’s lymphoma and infection with hepatitis E virus. To the best of our knowledge, this is the first ever reported case of VBDS associated with non-Hodgkin’s lymphoma and hepatitis E virus infection.
- Open Access
- 7 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12)
Delayed Spontaneous Regression of Metastatic Gastric Cancer: A Case Report of a Rare Finding
We discuss the case of a 74-year-old male who was referred with episodes of vomiting, nausea, and weight loss. Ultrasound abdomen had suggested multiple liver metastases and a triple-phase CT scan of abdomen-pelvis confirmed the same. His oesophago-gastro-duodenoscopy (OGD), also known as upper endoscopy (EGD), showed a large ulcerated lesion at the lesser curvature, which was later confirmed to be poorly differentiated adenocarcinoma on biopsy. The patient was started on palliative chemotherapy, which he tolerated poorly, but a CT scan had suggested a minimal reduction in the size of liver metastasis. He was given two cycles of chemotherapy; however, due to poor tolerance and unresponsiveness to chemotherapy, he was referred to palliative care. The patient declined any medical support for the next six years, after which he visited his general practitioner (GP) for a follow-up review. Routine blood tests showed new-onset mild iron deficiency anaemia. He denied any symptoms. He was referred to Gastroenterology for repeat OGD, and it showed a tiny nodular area in the stomach at the site of previous cancer, which was reported as non-specific chronic inflammation on biopsy, and CT abdomen showed a marked reduction in size and number of liver metastases. On further clinical review, he reported feeling well and his anaemia resolved without any intervention.
- 7 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12)
Open AccessDelayed Spontaneous Regression of Metastatic Gastric Cancer: A Case Report of a Rare Finding
We discuss the case of a 74-year-old male who was referred with episodes of vomiting, nausea, and weight loss. Ultrasound abdomen had suggested multiple liver metastases and a triple-phase CT scan of abdomen-pelvis confirmed the same. His oesophago-gastro-duodenoscopy (OGD), also known as upper endoscopy (EGD), showed a large ulcerated lesion at the lesser curvature, which was later confirmed to be poorly differentiated adenocarcinoma on biopsy. The patient was started on palliative chemotherapy, which he tolerated poorly, but a CT scan had suggested a minimal reduction in the size of liver metastasis. He was given two cycles of chemotherapy; however, due to poor tolerance and unresponsiveness to chemotherapy, he was referred to palliative care. The patient declined any medical support for the next six years, after which he visited his general practitioner (GP) for a follow-up review. Routine blood tests showed new-onset mild iron deficiency anaemia. He denied any symptoms. He was referred to Gastroenterology for repeat OGD, and it showed a tiny nodular area in the stomach at the site of previous cancer, which was reported as non-specific chronic inflammation on biopsy, and CT abdomen showed a marked reduction in size and number of liver metastases. On further clinical review, he reported feeling well and his anaemia resolved without any intervention.
- Open Access
- 29 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Colovesical Fistulae: The Varying Aetiologies
The most common presenting symptoms of colovesical fistulae (CVF) are pneumaturia and fecaluria. The most important aspect remains not only to investigate the aetiology, and the degree of both severity and complexity, but also the subsequent influence of this on overall management. In a younger population, management usually consists of curative surgery. However, this may not be possible in older patients where surgical candidacy is a genuine concern and a clinical challenge arises relating to pursuing a conservative strategy. We attempted to briefly outline how two patients were managed with a similar non-surgical approach due to frailty. These cases attempt to highlight the importance of multi-disciplinary specialty input, with a view to optimising patient care.
- 29 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Open AccessColovesical Fistulae: The Varying Aetiologies
The most common presenting symptoms of colovesical fistulae (CVF) are pneumaturia and fecaluria. The most important aspect remains not only to investigate the aetiology, and the degree of both severity and complexity, but also the subsequent influence of this on overall management. In a younger population, management usually consists of curative surgery. However, this may not be possible in older patients where surgical candidacy is a genuine concern and a clinical challenge arises relating to pursuing a conservative strategy. We attempted to briefly outline how two patients were managed with a similar non-surgical approach due to frailty. These cases attempt to highlight the importance of multi-disciplinary specialty input, with a view to optimising patient care.
- Open Access
- 7 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15490
COVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?
With the introduction of large-scale vaccination programmes against the coronavirus disease 2019 (COVID-19), the world has now begun to visualise a possible end to the ongoing pandemic. As with any vaccination programme, reports of side effects have begun to emerge in the wake of vaccinations. Initial reports were about mild side effects, such as local inflammation, pain, and fever. However, as a significant number of the population began to receive various COVID-19 vaccines, reports of various other moderate to severe side effects have now started to emerge. Although these side effects seem to be rare, the symptoms can be severe, and information and guidelines on how to manage them are scarce. In this case series, we discuss the incidence of widespread rashes that develop in some individuals after receiving COVID-19 vaccines by both AstraZeneca (AstraZeneca plc, Cambridge, UK) and Pfizer-BioNTech (Pfizer Inc., Brooklyn, NY; BioNTech SE, Mainz, Germany). The systemic skin reaction varied from maculopapular rashes to papules and patches that were widespread and not simply localised to the vaccine injection site. Further clinical information, awareness, and guidelines for practicing clinicians need to be exigently provided as vaccination programmes approach completion and the incidences of moderate to severe side effects of COVID-19 vaccination are becoming more apparent and pervasive.
- 7 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15490
Open AccessCOVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?
With the introduction of large-scale vaccination programmes against the coronavirus disease 2019 (COVID-19), the world has now begun to visualise a possible end to the ongoing pandemic. As with any vaccination programme, reports of side effects have begun to emerge in the wake of vaccinations. Initial reports were about mild side effects, such as local inflammation, pain, and fever. However, as a significant number of the population began to receive various COVID-19 vaccines, reports of various other moderate to severe side effects have now started to emerge. Although these side effects seem to be rare, the symptoms can be severe, and information and guidelines on how to manage them are scarce. In this case series, we discuss the incidence of widespread rashes that develop in some individuals after receiving COVID-19 vaccines by both AstraZeneca (AstraZeneca plc, Cambridge, UK) and Pfizer-BioNTech (Pfizer Inc., Brooklyn, NY; BioNTech SE, Mainz, Germany). The systemic skin reaction varied from maculopapular rashes to papules and patches that were widespread and not simply localised to the vaccine injection site. Further clinical information, awareness, and guidelines for practicing clinicians need to be exigently provided as vaccination programmes approach completion and the incidences of moderate to severe side effects of COVID-19 vaccination are becoming more apparent and pervasive.